Article Figures & Data
Figures
- FIGURE 1.
FDG-positive local recurrence (arrow) in 49-y-old man who presented with negative 131I scan after thyroidectomy and two courses of radioiodine treatment of papillary thyroid cancer initially staged as pT2bN0M0 (A). No tumor remnants were seen after further surgery (B) and during follow-up (C). Consequently, hTg levels dropped from 30 μg/L (preoperative) to 5 μg/L (postoperative) and 11 μg/L (follow-up). Images show maximum-intensity projections in anterior views.
- FIGURE 2.
FDG-positive residual tumor and lymph node metastasis (arrows) in 57-y-old woman who presented after incomplete thyroidectomy and tumor resection of papillary thyroid cancer initially staged as pT4bN1Mx (A). FDG PET was performed to assess tumor extension and possible metastases before further surgery. Residual tumor masses were seen after additional surgery (B), and external irradiation yielded good response (C). After irradiation, hTg levels dropped from 24 to 1.5 μg/L. Images show maximum-intensity projections in anterior views.
Tables
FDG PET n Validation Histology Positive 131I CT or MRI hTg follow-up Cytology True-positive 34 17 8 9 0 0 False-positive 7 2 0 2 2 1 True-negative 5 0 0 0 5 0 False-negative 15 2 1 1 11 0 n = number of patients.
FDG PET n Treatment Surgery 131I therapy External irradiation NCTO NTN True-positive* 34 18 10 4 7 0 False-positive 7 2 0 0 0 5 True-negative 5 0 0 0 0 5 False-negative 15 3 1 0 11 0 ↵* Figures in first line exceed number of patients because some patients got more than one treatment (e.g., surgery and external irradiation).
n = number of patients; NCTO = no curative treatment option available because of widespread disease; NTN = no treatment necessary.
hTg (μg/L) TSH (μIU/mL) Σ >30 ≤0.1 <10 2/12 0/7 2/19 10≤20 3/6 1/2 4/8 20≤50 6/8 2/2 8/10 50≤100 4/7 1/1 5/8 >100 9/10 5/5 14/15 One patient could not be considered because his hTg level was unknown.
In this issue
Jump to section
Related Articles
Cited By...
- ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
- PET/CT fusion technology: its role in managing recurrent, well-differentiated thyroid cancer
- Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer
- 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer
- The contribution of PET/CT to improved patient management
- Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning
- Empirically Treating High Serum Thyroglobulin Levels
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- PET in the follow-up of differentiated thyroid cancer
- Clinical Usefulness of FDG PET in Differentiated Thyroid Cancer